Iift arboviral fever mosaic igg and igm

Pregnant women were eligible for recruitment when transferred to referral hospitals for the reasons specified above. At recruitment, we collected demographic data, including maternal birth date, birth country, ZIKV exposure country, presence of symptoms, and departure and return dates from ZIKV endemic area. Likewise, blood and/or urine ZIKV samples were collected and analyzed via RT-PCR commercial assay (RealStar® Zika Virus RT-PCR kit 1.0, Altona Diagnostics), ZIKV-IgG, and ZIKV-IgM (IIFT Arboviral fever Mosaic IgG and IgM, Euroimmun, Germany from 2016 to December 2017; and ELISA Virus Zika IgG and IgM, Euroimmun, Germany, from December 2017 to the end of study) (Table 1). If ZIKV RT-PCR was negative but ZIKV-IgG tested positive, specimens were sent to the Instituto de Salud Carlos III (ISCIII, Madrid, Spain) for ZIKV-PRNT. However, ISCIII was not able to perform specific PRNT for DENV; consequently, positive or equivocal ZIKV-PRNT titers were not compared with DENV-PRNT results. Neutralization titer ≥1/32 was considered indicative of the presence of ZIKV neutralizing antibodies. The date of ZIKV test was considered to be the date of diagnosis for ZIKV infection.

All the pregnant women testing positive for ZIKV-IgG or ZIKV-IgM and (i) travelling to endemic areas during the pregnancy or the two previous months, or (ii) who had sexual partners that had visited endemic areas in the last 6 months were eligible for recruitment.
We collected demographic data, blood, and/or urine samples to test for ZIKV, and the samples were collected and analyzed with reverse transcriptase polymerase chain reaction (RT-PCR) (RealStar^®Zika Virus RT-PCR kit 1.0, Altona Diagnostics), ZIKV-IgG, and ZIKV-IgM (IIFT Arboviral fever Mosaic IgG and IgM, Euroimmun, Germany from 2016 to December 2017; and ELISA Virus Zika IgG and IgM, Euroimmun, Germany, from December 2017 to the end of study) (Table 1). In cases where ZIKV RT-PCR tested negative but ZIKV-IgG was positive, samples were shipped to the national reference laboratory Instituto de Salud Carlos III (ISCIII) located in Madrid. They processed the samples using a specific plaque reduction neutralization test for ZIKV (ZIKV-PRNT). Unfortunately, ISCIII did not perform PRNT for other flaviviruses; therefore, positive ZIKV-PRNT titers were not able to be compared with other flaviviruses. A neutralization titer ≥1/32 was considered positive, detecting the presence of ZIKV-neutralizing antibodies. The ZIKV test date was considered to be the diagnosis date for ZIKV infection [12 (link)].